In 191 cannabis users, frequent users had higher residual THC in blood and longer detection times, while oral fluid showed less difference between user types, complicating per se driving laws.
Forensic toxicologists, law enforcement, policymakers working on cannabis-impaired driving laws.
Oral fluid THC at 10 ng/mL: 99.7% specificity, 82.4% sensitivity for recent use
What the researchers found
Frequent users had higher residual blood THC and were more likely to test positive before even smoking. Per se blood THC limits (up to 5 ng/mL) offered limited usefulness as biomarkers of recent use. Blood CBN at 1 ng/mL cutoff had 100% specificity but only 31.4% sensitivity. Oral fluid THC at 10 ng/mL showed the best overall performance (99.7% specificity, 82.4% sensitivity) for detecting use within 3 hours, but was still detectable in 23.2% of participants 4.4 hours post-smoking.
Why it matters
Several states have adopted per se THC driving limits, but this study shows these limits perform poorly at identifying recent use, especially in frequent users who may test positive without having used recently. This has direct implications for roadside testing fairness.
The numbers in context
191 users (frequent and occasional). Blood THC ≥5 ng/mL at 6 hours: 14%. Oral fluid THC ≥5 ng/mL at 6 hours: 54%. Oral fluid THC 10 ng/mL cutoff: 99.7% specificity, 82.4% sensitivity for 3-hour window. Blood CBN 1 ng/mL: 100% specificity, 31.4% sensitivity.
How the study worked
Randomized trial of 191 frequent (4+ times/week) and occasional (<4/week) cannabis users who smoked placebo, 5.9%, or 13.4% THC cannabis ad libitum. Blood, oral fluid, and breath samples collected before and up to 6 hours after smoking. Ten cannabinoids measured in oral fluid, 8 in blood, THC in breath via LC-MS/MS.
What this study cannot tell us
Only tested smoked cannabis, not edibles or other routes. Laboratory conditions may not reflect real-world use. Detection windows may vary with different cannabis products. CBN levels may vary by cannabis strain.
How to read the evidence
Well-designed randomized trial with controlled dosing and multiple matrices measured by gold-standard LC-MS/MS. Strong for pharmacokinetic characterization.
When this study was published
2021 controlled dosing study.
The bigger picture
The fundamental problem with cannabis impaired driving laws is that no biomarker cleanly separates "recently used and likely impaired" from "used days ago and not impaired." This study quantifies that gap and suggests oral fluid may be better than blood, but neither is sufficient without behavioral assessment.
Questions still open
- Would edible cannabis produce different detection profiles? Can combining multiple biomarkers improve accuracy? Should per se THC driving limits be abandoned in favor of behavioral assessment?
Common questions
Can a blood test accurately tell if someone recently used cannabis?
Is oral fluid testing better than blood for cannabis DUI?
Read the original research
Blood and Oral Fluid Cannabinoid Profiles of Frequent and Occasional Cannabis Smokers.
Journal of analytical toxicology, 45(8), 851-862
Citation
Hoffman, Melissa A; Hubbard, Jacqueline A; Sobolesky, Philip M; Smith, Breland E; Suhandynata, Raymond T; Sanford, Sandra; Sones, Emily G; Ellis, Shannon; Umlauf, Anya; Huestis, Marilyn A; Grelotti, David J; Grant, Igor; Marcotte, Thomas D; Fitzgerald, Robert L. (2021). Blood and Oral Fluid Cannabinoid Profiles of Frequent and Occasional Cannabis Smokers.. Journal of analytical toxicology, 45(8), 851-862. https://doi.org/10.1093/jat/bkab078